ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±¼òÎÄÑî¡¢´÷Ï£°²£©ÀúʱÁùÄ꣬£¬¿ËÈÕ£¬£¬À´×Ôngµç×ÓÓÎÏ·Á¥ÊôµÚÁùÒ½Ôº½áÖ±³¦¸ØÃÅÍâ¿ÆÍô½¨Æ½¡¢¿µÁÁÍŶÓÐû²¼ÁËÖ±³¦°©Íâ¿ÆÖÎÁÆÁìÓòµÄÖ÷ÒªÑо¿Ð§¹û¡ª¡ªÈ«ÇòÊ׸ö¾¸ØÈ«Ö±³¦ÏµÄ¤ÇгýÊõ(transanal total mesorectal excision, taTME)ÖÎÁÆÖ±³¦°©µÄ¶àÖÐÐÄËæ»ú±ÈÕÕÁÙ´²Ñо¿¶ÌÆÚЧ¹û¡£¡£¡£
¾Ý½éÉÜ£¬£¬¸ÃÑо¿Ê×´Îͨ¹ý¸ß¼¶±ðÖ¤¾Ý֤ʵtaTMEÖÎÁÆÖ±³¦°©Çå¾²¿ÉÐУ¬£¬taTME¿ÉÔÚ°ü¹ÜÊÖÊõÖÊÁ¿µÄÌõ¼þÏ£¬£¬Ê¹²¡ÈËÓÐÒ»¶¨µÄ΢´´Íâ¿Æ»ñÒæ£¬£¬Èç½øÊ³Ô硢ϴ²»î¶¯¿ì¡¢³¦µÀÅÅÆø¹¦Ð§»Ö¸´Ê±¼ä¶ÌµÈÓÅÊÆ£¬£¬ÎªÖ±³¦°©µÄÊÖÊõÖÎÁÆÌṩÁËÖйúÂÄÀú£¡£¡
Ïà¹ØÐ§¹ûÒÔ¡°Morbidity, Mortality, and Pathologic Outcomes of Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer Short-term Outcomes From a Multicenter Randomized Controlled Trial¡±£¨¾¸ØÈ«Ö±³¦ÏµÄ¤ÇгýÊõÖÎÁÆÖ±³¦°©µÄ¶àÖÐÐÄËæ»ú±ÈÕÕÁÙ´²Ñо¿¶ÌÆÚЧ¹û£ºÊÖÊõÏà¹Ø²¢·¢Ö¢¼°²¡ÀíÇгýÖÊÁ¿£©ÎªÌâÔÚÍâ¿ÆÑ§ÁìÓòȨÍþÆÚ¿¯Annals of Surgery¡¶Íâ¿ÆÑ§Äê¼ø¡·£©ÒÔÔ´´ÂÛÖøÐÎʽÔÚÏß½ÒÏþ¡£¡£¡£
º£ÄÚ·¢²¡ÂʾӸ߲»Ï£¬£¬¹Å°åÇгýÊõ½øÍËά¹È
½áÖ±³¦Ö×ÁöÔÚÖйúÐÎÊÆÑÏË࣬£¬ÔÚÉϺ£¡£¡¢Ïã¸Û¡¢¹ãÖݵȳÇÊз¢²¡ÂÊÒѾÅÅÔÚµÚ¶þ룬£¬ÓëÃÀ¹úµÈÎ÷·½¹ú¼ÒÏà·´£¬£¬ÎÒ¹úµÄ·¢²¡ÂÊ»¹ÔÚÉÏÉý£¬£¬ÑÏÖØÍþвÎÒ¹úסÃñÉúÃü¿µ½¡¡£¡£¡£¸¹Ç»¾µÏÂȫֱ³¦ÏµÄ¤ÇгýÊõÊÇÏÖÔÚÁÙ´²ÖÎÁÆÖ±³¦°©µÄ×îÖ÷ÒªÊֶΡ£¡£¡£È»¶ø£¬£¬¹ØÓÚ½áÖ±³¦Íâ¿ÆÒ½ÉúÀ´Ëµ£¬£¬ÔÚ´¦ÀíÉæ¼°µÍλֱ³¦µÄ¼²²¡Ê±£¬£¬ÓÉÓÚ¹ÇÅè¹ÇÐԽṹµ¼ÖµÄÏÁտռ估ÖÜΧÆ÷¹ÙµÄÓ°Ï죬£¬¹Å°å¾¸¹¼°ÆäËûÊÖÊõÈë·ÄÑÒÔ½â¾öÊõÖеÄÏÔ¶ÎÊÌ⣬£¬´Ó¶øÄÑÒÔ¾«×¼µØÇгý²¡Ô£¬µ¼Ö¼²²¡Êõºó²ÐÁô¸´·¢£¬£¬Òà»òÊÇÍâ¿ÆÒ½ÉúΪÁËÈ·±£ÍêÈ«Çгý²¡Ôî¶ø²»µÃ²»À©´óÇгý¹æÄ££¬£¬´Ó¶øÔö´óÁË´´ÉËÉõÖÁµ¼Ö²»¿ÉÄæÐÔµÄÆ÷¹Ù¹¦Ð§ËðÉË¡£¡£¡£

¿µÁÁÖ÷ÈÎҽʦÍŶÓÔÚΪֱ³¦°©»¼Õß¿ªÕ¹taTME±£¸ØÊÖÊõ£¨ÉãÓ°£ºÕÅԴȪ£©
Ìá³ötaTME±£¸ØÐÂÊÖÒÕ£¬£¬ÒµÒÑÍê³É̽Ë÷ºÍ¿ªÕ¹½×¶Î
¾¸ØÈë·ÄÜÀÖ³ÉÆÆ½âÒÔÉÏÎÊÌ⣬£¬×ÔÎÊÊÀÊ®ÓàÄêÀ´£¬£¬Á¬ÏµÇ»¾µÊÖÒÕ¼°×ÔȻǻÔÀíÄîµÄ taTMEÊõʽ³ÉΪÁËÈ´Ö±³¦Íâ¿ÆµÄÁÙ´²ÈÈÃÅ¡£¡£¡£¾Ý¿µÁÁ½éÉÜ£¬£¬¸ÃÊõʽ¾×ÔȻǻµÀ£¨¾¸Ø£©Èë·£¬£¬Ê×ÏÈ´¦Àí±£¸ØÄѶÈ×î´óµÄÖ×ÁöÔ¶¶Ë²¿·Ö£¬£¬ÔÚ°ü¹ÜÖ×Áö¸ùÖεÄÌõ¼þÏÂÄÜ×î´óÏ޶ȱ£´æ¸ØÃÅ£¬£¬¼«´ó³Ì¶ÈµÄÌá¸ßÁ˵Íλֱ³¦°©µÄ±£¸ØÂÊ¡£¡£¡£Õë¶Ô¸ÃÏî±£¸ØÐÂÊÖÒÕ£¬£¬Á¥ÊôÁùÔºÍô½¨Æ½¡¢¿µÁÁÍŶÓÔÚ2014ÄêÊ×ÏÈÔÚº£ÄÚÆ¾Ö¤IDEAL(The Idea, Development, Exploration, Assessment, Long term study framework)ÐÂÊÖÒÕ¹ú¼Ê±ê×¼£¬£¬ÏµÍ³ÐÔ¿ªÕ¹taTMEÊÖÊõ£¬£¬ÒÑÍê³ÉÁËtaTMEÇå¾²ÐԺͿÉÐÐÐÔµÄ̽Ë÷ºÍ¿ªÕ¹½×¶Î£¬£¬Ïà¹ØÑо¿Ð§¹ûÔÚÃÀ¹ú½áÖ±³¦Íâ¿ÆÒ½Ê¦Ñ§»á¹Ù·½ÔÓÖ¾DISEASES OF THE COLON & RECTUMÉϽÒÏþ(2021;64(4):380-388)¡£¡£¡£È»¶ø£¬£¬taTME×÷ΪһÏîÐÂÐË΢´´Êõʽ£¬£¬ÆäÖ×ÁöѧÁÆÐ§ÉÐÐèÒª´ó¹æÄ£µÄËæ»ú±ÈÕÕÑо¿µÈ¸ß¼¶±ðÖ¤¾ÝµÄÖ§³Ö¡£¡£¡£

ƾ֤IDEAL¿ò¼Ü£¬£¬¸ÃÍŶӿªÕ¹µÄÂäʵtaTME±£¸ØÐÂÊÖÒÕ̽Ë÷ºÍ¿ªÕ¹½×¶ÎÑо¿Ð§¹û
ÁªºÏ¶à¼ÒÒ½ÔºÕö¿ªTaLaRÑо¿£¬£¬¸ß¼¶±ðҽѧ֤¾ÝÖ¸ÈÕ¿É´ý
Òò´Ë£¬£¬ÎªÁË̽Ë÷taTMEÔÚÖ±³¦°©ÖÐÇå¾²ÐÔºÍÓÐÓÃÐÔ£¬£¬ÓÉÁ¥ÊôµÚÁùÒ½ÔºÍô½¨Æ½¡¢¿µÁÁÍŶÓǣͷ£¬£¬±±¾©¡¢ÉϺ£¡£¡¢¹ã¶«¡¢¼ªÁÖ¡¢ºþÄÏ¡¢ÖØÇì¡¢ËÄ´¨¡¢ÉÂÎ÷¡¢¹óÖÝ¡¢ÁÉÄþµÈÌìϹ²16¼ÒÈý¼×Ò½Ôº¼ÓÈëµÄ¡°¾¸ØÃÅȫֱ³¦ÏµÄ¤ÇгýÊõÖÎÁÆÖеÍλֱ³¦°©µÄǰհÐÔ¡¢¶àÖÐÐÄ¡¢Ëæ»ú¡¢¿ª·Å¡¢Æ½ÐбÈÕÕ¡¢·ÇÁÓЧÁÙ´²Ñо¿£¨TaLaR£©¡±ÓÚ2016Äê4ÔÂÕýʽÆô¶¯£¬£¬2021Äê6ÔÂÍê³É1115ÀýÊÜÊÔÕßÈë×é¡£¡£¡£TaLaRÆðԴЧ¹ûÏÔʾ£ºtaTMEʵÑé×éÓ븹ǻ¾µTME±ÈÕÕ×é¿ÉʵÏÖÏàËÆµÄÊÖÊõÇгýÖÊÁ¿£¬£¬ÑÏÖØ²»Á¼ÊÂÎñµÄ±¬·¢ÂÊ»®·ÖΪ4.8%ºÍ3.9%£¬£¬Á½ÕߵIJî±ð¾ùÎÞͳ¼ÆÑ§ÒâÒå¡£¡£¡£ÏÖÔÚ£¬£¬TaLaRÑо¿ÊÜÊÔÕßËæ·ÃÐÅÏ¢µÄÍêÕû¶ÈµÖ´ï95%ÒÔÉÏ£¬£¬Ô¤¼Æ2023Äêµ×¿ÉÍê³ÉÊõºó3ÄêÖ×ÁöѧÁÆÐ§µÄÆÀ¹À¡£¡£¡£Íô½¨Æ½Ö¸³ö£¬£¬¡°Ïà±È¹ú¼ÊͬÆÚ¿ªÕ¹µÄÀàËÆÑо¿£¬£¬ÎÒÃÇÔ¤¼ÆÍê³Éʱ¼äÁìÏÈÔ¼3Äꡱ£¬£¬TaLaRÑо¿ÓÐÍû³ÉΪÊ׸öÖ§³ÖtaTMEÁÙ´²Ó¦Óõĸ߼¶±ðÑ֤ҽѧ֤¾Ý¡£¡£¡£

Á¥ÊôµÚÁùÒ½ÔºÍô½¨Æ½¡¢¿µÁÁÍŶӳÉÔ±ºÏÕÕ
¾ÝÏàʶ£¬£¬ÒÔÖйú¾¸ØÇ»¾µÍâ¿ÆÑо¿Ð×÷×é(CTESC)ºÍÖйúҽʦлáÍâ¿Æ·Ö»á¾¸ØÃÅȫֱ³¦ÏµÄ¤ÇгýÊõרҵίԱ»áΪƽ̨£¬£¬Á¥ÊôµÚÁùÒ½Ôº×÷ΪPIµ¥Î»ÔÚÖ±³¦°©Íâ¿ÆÖÎÁÆÁìÓò¸û×÷²»ê¡£¬£¬ÕâÊǼÌÇ£Í·ÖÆ¶©º£ÄÚÊ׸ö¡¶Ö±³¦°©¾¸ØÃÅȫֱ³¦ÏµÄ¤ÇгýÊõר¼ÒÒâ¼û£¨2015°æ£©¡·¡¢¡¶Öйú¾¸ØÇ»¾µÍâ¿ÆÑ§ÔºÅàѵϵͳ£¨2018°æ£©¡·ºÍ¡¶Öйú¾¸ØÇ»¾µÍâ¿Æ×¨¼Ò¹²Ê¶£¨2019°æ£©¡·£¬£¬³öÊ麣ÄÚÊײ¿¡¶¾¸ØÈ«Ö±³¦ÏµÄ¤ÇгýÊõ¡·£¨ÈËÃñÎÀÉú³öÊéÉç£©×¨Öøºó£¬£¬¸ÃÔº½áÖ±³¦¸ØÃÅÍâ¿ÆÍŶӼÌÐø¿ªÍؽøÈ¡£¬£¬Ð¢Ë³ÖйúÂÄÀúºÍÖ¤¾Ý£¬£¬ÒýÁìÁÙ´²Ö¸ÄÏÓÅ»¯¡£¡£¡£
ÂÛÎÄÁ´½Ó£ºhttps://pubmed.ncbi.nlm.nih.gov/35815886/